Drugs / GSK1557484A
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT02719743 | Jul 2016 → Feb 2018 | influenza | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT01045564 | Jan 2011 → Feb 2013 | influenza | GlaxoSmithKline | Withdrawn | No outcome recorded |
| Phase 2 | NCT00719043 | Jul 2008 → Apr 2010 | influenza | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01310413 | Mar → Jul 2011 | influenza | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK 1557484A | “Three doses of GSK 1557484A administered intramuscularly (IM), the first and third in the deltoid region of the non-dominant arm and the second in the deltoid region of the dominant arm” NCT01045564 ↗3“This study will assess safety and immunogenicity of GSK Biologicals' H5N1 flu candidate vaccine GSK1557484A in children 6 months to \< 18 years of age.” NCT01310413 ↗ “GSK's avian flu vaccine GSK 1557484A” NCT00719043 ↗ |
| Modality | Vaccine | “avian flu vaccine” NCT00719043 ↗ |
| Route | Intramuscular | “Administered as an intramuscular (IM) injection” NCT00719043 ↗ |